Rare disease clinical trials: the urgent need for patients to be heard

Betsy Goodfellow | May 22, 2024 | Feature | |  Alexion, Pharmafocus, Rare Diseases, clinical trials, feature 

Ahead of Clinical Trials Day, Soraya Bekkali, from Alexion, AstraZeneca Rare Disease, highlights the urgent need to elevate patients’ voices to accelerate rare disease innovation

Recent estimates show that the number of rare disease clinical trials has risen over recent years, with over 16,000 studies being conducted across the globe.1 While we must celebrate this progress, there remains an urgent need to accelerate innovation, with no meaningful treatment options for 90% of the 10,000 known rare diseases.2 Critical to clinical trial success is ensuring the voices of people living with rare diseases are amplified and heard.3,4

Read more at: https://www.pharmafocus.com/collections/may-2024/rare-disease-clinical-trials-the-urgent-need-for-patients-to-be?fullscreen=false

Related Content

AstraZeneca’s tozorakimab cuts COPD exacerbations by up to 34% in phase 3 trials

AstraZeneca’s tozorakimab reduced moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease (COPD) in two …

Clinical trials don’t just have a recruitment problem, they have an enrolment protection problem.

By Dr. Richard Graham Industry conversations about clinical trial participation tend to focus on awareness, …

EMA selects TrialAssure anonymisation platform for clinical trial documents

TrialAssure has announced that its ANONYMIZE platform has been selected by the European Medicines Agency …

The Gateway to Local Adoption Series

Latest content